Key Points
- Nurix Therapeutics insider Gwenn Hansen sold 1,452 shares at an average price of $26.80, generating $38,913.60. The Rule 10b5-1 sale was intended to cover tax withholding tied to vested equity awards, leaving Hansen with 123,452 shares.
- NRIX shares opened at $25.70, with a market capitalization of approximately $2.81 billion and a 52-week range of $11.67 to $28.23. The company recently reported quarterly EPS of $4.73, substantially above the consensus estimate of a $0.60 loss.
- Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” from 15 analysts and an average price target of $34.79. Several firms recently raised their targets, including Morgan Stanley to $38 and Stifel Nicolaus to $41.
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 1,452 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $26.80, for a total transaction of $38,913.60. Following the transaction, the insider owned 123,452 shares in the company, valued at $3,308,513.60. This trade represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Gwenn Hansen also recently made the following trade(s):
- On Friday, October 30th, Gwenn Hansen sold 3,957 shares of Nurix Therapeutics stock. The shares were sold at an average price of $26.28, for a total value of $103,989.96.
- On Thursday, October 15th, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $36,300.00.
- On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total transaction of $36,982.44.
- On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00.
- On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total value of $100,143.96.
Nurix Therapeutics Stock Down 4.1%
Shares of NASDAQ:NRIX opened at $25.70 on Tuesday. Nurix Therapeutics, Inc. has a fifty-two week low of $11.67 and a fifty-two week high of $28.23. The company's 50-day moving average price is $24.96 and its 200 day moving average price is $20.23. The company has a market cap of $2.81 billion, a PE ratio of 11.13 and a beta of 1.82.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings results on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. The company had revenue of $673.06 million during the quarter, compared to analysts' expectations of $24.35 million. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. As a group, equities analysts anticipate that Nurix Therapeutics, Inc. will post 1.14 EPS for the current year.
Analysts Set New Price Targets
NRIX has been the subject of several analyst reports. Morgan Stanley upped their target price on Nurix Therapeutics from $36.00 to $38.00 and gave the company an "overweight" rating in a report on Tuesday, July 28th. Stifel Nicolaus set a $41.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, October 13th. Wall Street Zen raised shares of Nurix Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, October 17th. Oppenheimer boosted their price objective on Nurix Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Tuesday, October 13th. Finally, Robert W. Baird upped their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the company an "outperform" rating in a research report on Tuesday, October 13th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.79.
View Our Latest Report on NRIX
Institutional Trading of Nurix Therapeutics
A number of institutional investors have recently bought and sold shares of NRIX. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Nurix Therapeutics in the 3rd quarter valued at $126,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Nurix Therapeutics by 15.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,936 shares of the company's stock worth $448,000 after purchasing an additional 2,479 shares during the last quarter. Sterling Capital Management LLC grew its stake in shares of Nurix Therapeutics by 310.4% during the third quarter. Sterling Capital Management LLC now owns 2,885 shares of the company's stock worth $68,000 after purchasing an additional 2,182 shares during the period. GAMMA Investing LLC grew its stake in shares of Nurix Therapeutics by 95.4% during the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company's stock worth $30,000 after purchasing an additional 620 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in shares of Nurix Therapeutics by 755.9% during the third quarter. Farther Finance Advisors LLC now owns 4,014 shares of the company's stock worth $95,000 after purchasing an additional 3,545 shares during the period.
Nurix Therapeutics Company Profile
(
Get Free Report)
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.
The company's pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton's tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
